High-Dose Rituximab Ineffective for Focal Segmental Glomerulosclerosis: A Long-Term Observation Study.
Roccatello, Dario; Sciascia, Savino; Rossi, Daniela; Alpa, Mirella; Naretto, Carla; Radin, Massimo; Barreca, Antonella; Fenoglio, Roberta; Baldovino, Simone; Menegatti, Elisa.
Am J Nephrol
; 46(2): 108-113, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28700988
ATRA attenuate proteinuria via downregulation of TRPC6 in glomerulosclerosis rats induced by adriamycin.
Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy.
Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach.
Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.
Urinary CD80 excretion is a predictor of good outcome in children with primary nephrotic syndrome.
Successful treatment of recurrent focal segmental glomerulosclerosis with a low dose rituximab in a kidney transplant recipient.
Wilms' tumour 1 gene mutations in south Indian children with steroid-resistant nephrotic syndrome.
Intravenous Rituximab in Severe Refractory Primary Focal Segmental Glomerulosclerosis.
Ofatumumab for the treatment of childhood nephrotic syndrome.
Advances in molecular diagnosis and therapeutics in nephrotic syndrome and focal and segmental glomerulosclerosis.